Table 2 Subgroup analysis of overall survival and disease-free survival
Subgroup | No. of datasets | HR | 95% CI | I2 | Model |
|---|---|---|---|---|---|
OS | |||||
Single tumor ≤ 2 cm | 4 | 1.40 | 0.93–2.11 | 0% | Fixed |
Single tumor ≤ 3 cm | 8 | 1.19 | 0.90–1.58 | 0% | Fixed |
Single tumor ≤ 5 cm | 17 | 1.17 | 1.05–1.29 | 0% | Fixed |
LH | 6 | 1.33 | 0.87–2.03 | 0% | Fixed |
NAR | 3 | 1.81 | 1.05–3.10 | 0% | Fixed |
PSM | 31 | 1.24 | 1.14–1.34 | 38% | Fixed |
RCT | 5 | 1.09 | 0.86–1.37 | 0% | Fixed |
Sample size < 100 | 23 | 1.14 | 0.95–1.36 | 0% | Fixed |
Sample size > 100 | 13 | 1.26 | 1.03–1.53 | 63% | Random |
Asia | 32 | 1.2 | 1.11–1.30 | 22% | Fixed |
Europe | 4 | 1.24 | 0.70–2.20 | 69% | Random |
China | 21 | 1.21 | 1.11–1.31 | 21% | Fixed |
Published after 2015 | 26 | 1.26 | 1.16–1.37 | 33% | Fixed |
Published on or before 2015 | 10 | 1.03 | 0.86–1.24 | 14% | Fixed |
Surgical margin > 1 cm | 4 | 1.25 | 0.93–1.68 | 35% | Fixed |
Ablation margin > 0.5 cm | 9 | 1.29 | 1.09–1.53 | 0% | Fixed |
Ablation margin > 1 cm | 6 | 1.12 | 0.67–1.86 | 54% | Random |
RFS | |||||
Single tumor ≤ 2 cm | 3 | 1.51 | 0.85–2.69 | 70% | Random |
Single tumor ≤ 3 cm | 8 | 1.45 | 1.11–1.90 | 66% | Random |
Single tumor ≤ 5 cm | 15 | 1.55 | 139–1.73 | 30% | Fixed |
LH | 7 | 1.78 | 1.32–2.39 | 59% | Random |
NAR | 2 | 1.48 | 1.09–2.02 | 0% | Fixed |
PSM | 25 | 1.64 | 1.51–1.78 | 35% | Fixed |
RCT | 6 | 1.15 | 0.98–1.35 | 38% | Fixed |
Sample size < 100 | 20 | 1.68 | 1.50–1.88 | 33% | Fixed |
Sample size > 100 | 11 | 1.42 | 1.20–1.67 | 62% | Random |
Asia | 28 | 1.54 | 1.36–1.73 | 52% | Random |
Europe | 3 | 1.83 | 1.43–2.34 | 0% | Fixed |
China | 19 | 1.54 | 1.34–1.77 | 54% | Random |
Published after 2015 | 25 | 1.63 | 1.43–1.86 | 53% | Random |
Published on or before 2015 | 6 | 1.52 | 1.41–1.64 | 3% | Fixed |
Surgical margin > 1 cm | 4 | 1.69 | 1.38–2.06 | 8% | Fixed |
Ablation margin > 0.5 cm | 7 | 1.42 | 1.22–1.66 | 0% | Fixed |
Ablation margin > 1 cm | 5 | 1.56 | 1.31–1.86 | 3% | Fixed |